STEPS™:: A comprehensive program for controlling and monitoring access to thalidomide

被引:163
作者
Zeldis, JB [1 ]
Williams, BA [1 ]
Thomas, SD [1 ]
Elsayed, ME [1 ]
机构
[1] Celgene Corp, Dept Med Affairs, Warren, NJ 07059 USA
关键词
congenital abnormalities; teratogenicity; thalidomide; patient education; prevention;
D O I
10.1016/S0149-2918(00)88289-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In July 1998, the US Food and Drug Administration approved the marketing of thalidomide for the treatment of cutaneous manifestations of erythema nodosum leprosum. To ensure that fetal exposure to this teratogenic agent does not occur, the manufacturer has instituted a comprehensive program to control prescribing, dispensing, and use of the drug. This program, known as the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.(TM) [Celgene Corporation, Warren, New Jersey]), is based in part on experience gained with other drugs-specifically isotretinoin and clozapine-that offer important clinical benefits but carry the potential for serious harm. To achieve its goal of the lowest possible incidence of drug-associated teratogenicity, the S.T.E.P.S.(TM) program uses a three-pronged approach: (1) controlling access to the drug; (2) educating prescribers, pharmacists, and patients; and (3) monitoring compliance. Clinicians who wish to prescribe thalidomide must be registered in the S.T.E.P.S.(TM) Prescriber Registry and agree to prescribe the drug in accordance with S.T.E.P.S.(TM) patient eligibility criteria and monitoring procedures. Pharmacies must also register and agree to comply with patient identification and monitoring criteria. Finally, patients receive visual aids, including a videotape, written material, and verbal counseling about the benefits and risks of thalidomide therapy, the importance of not becoming pregnant during therapy, and the types of contraception required (including emergency contraception) and their availability. Women of childbearing potential must agree to undergo pregnancy testing before starting therapy and on a regular schedule during therapy. All patients must agree to complete a confidential survey about their compliance with contraception, testing, and drug therapy. The manufacturer is monitoring survey results and outcome data and is prepared to make whatever modifications to the S.T.E.P.S.(TM) program are necessary to ensure its effectiveness. In addition to minimizing the potential risk for fetal harm associated with thalidomide therapy, the S.T.E.P.S.(TM) program may provide a model for future cases in which a drug offers compelling benefits but poses profound risks unless its distribution is carefully controlled.
引用
收藏
页码:319 / 330
页数:12
相关论文
共 17 条
[1]  
Calabrese L, 1998, Expert Opin Investig Drugs, V7, P2043, DOI 10.1517/13543784.7.12.2043
[2]  
GARDNERMEDWIN JM, 1996, EXPERT OPIN INV DRUG, V5, P829
[3]  
GUNZLER V, 1992, DRUG SAFETY, V7, P116
[4]  
Honigfeld G, 1996, PSYCHIATR SERV, V47, P52
[5]  
IYER CGS, 1971, B WORLD HEALTH ORGAN, V45, P719
[6]  
KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
[7]   CLOZAPINE FOR THE TREATMENT-RESISTANT SCHIZOPHRENIC - RESULTS OF A UNITED-STATES MULTICENTER TRIAL [J].
KANE, JM ;
HONIGFELD, G ;
SINGER, J ;
MELTZER, H .
PSYCHOPHARMACOLOGY, 1989, 99 :S60-S63
[8]   DIE THALIDOMID-EMBRYOPATHIE [J].
LENZ, W ;
KNAPP, K .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1962, 87 (24) :1232-&
[9]  
MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305
[10]   NEUROPATHY TO EMBRYOPATHY, WITH CASE REPORTS OF CONGENITAL ANOMALIES [J].
MELLIN, GW ;
KATZENSTEIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1962, 267 (24) :1238-&